Florida 2025 Regular Session

Florida House Bill H1093 Compare Versions

Only one version of the bill is available at this time.

Old	New	Differences
1	1
2	2
3	3	HB 1093 2025
4	4
5	5
6	6
7	7	CODING: Words stricken are deletions; words underlined are additions.
8	8	hb1093-00
9	9	Page 1 of 3
10	10	F L O R I D A H O U S E O F R E P R E S E N T A T I V E S
11	11
12	12
13	13
14	14	A bill to be entitled 1
15	15	An act relating to coverage of prescription drugs for 2
16	16	pain; creating ss. 409.9064 and 409.9746, F.S.; 3
17	17	defining the term "nonopioid pain drug"; requiring the 4
18	18	Medicaid program and Medicaid managed care plans, 5
19	19	respectively, to provide coverage such that nonopioid 6
20	20	pain drugs are not disadvantaged or otherwise 7
21	21	discouraged relative to any opioid or narcotic drug 8
22	22	for pain management or treatment; specifying 9
23	23	prohibited practices in relation to such coverage; 10
24	24	providing an effective date. 11
25	25	12
26	26	Be It Enacted by the Legislature of the State of Florida: 13
27	27	14
28	28	Section 1. Section 409.9064, Florida Statutes, is created 15
29	29	to read: 16
30	30	409.9064 Coverage of prescription drugs for pa in.— 17
31	31	(1) As used in this section, the term "nonopioid pain 18
32	32	drug" means a nonopioid drug approved by the United States Food 19
33	33	and Drug Administration for the treatment or management of pain. 20
34	34	(2) The agency shall provide coverage that does not 21
35	35	disadvantage or otherwise discourage a nonopioid pain drug 22
36	36	relative to any opioid or narcotic drug for the treatment or 23
37	37	management of pain. Prohibited practices or policies for such 24
38	38	coverage include, but are not limited to, the following: 25
39	39
40	40	HB 1093 2025
41	41
42	42
43	43
44	44	CODING: Words stricken are deletions; words underlined are additions.
45	45	hb1093-00
46	46	Page 2 of 3
47	47	F L O R I D A H O U S E O F R E P R E S E N T A T I V E S
48	48
49	49
50	50
51	51	(a) Designating a nonopioid pain drug as a nonpreferred 26
52	52	drug if any opioid or narcotic drug is designated as a preferred 27
53	53	drug on the mandatory preferred drug list. 28
54	54	(b) Establishing utilization controls for a nonopioid pain 29
55	55	drug which are more restrictive or more extensive than the least 30
56	56	restrictive or extensive utilization controls applicable to any 31
57	57	opioid or narcotic drug used for treatment of the same 32
58	58	condition, including, but not limited to, imposing more 33
59	59	restrictive or more extensive prior authorization or step -34
60	60	therapy requirements for the nonopioid pain drug. 35
61	61	Section 2. Section 409.9746, Florida Statutes, is created 36
62	62	to read: 37
63	63	409.9746 Managed care plan coverage of prescription drugs 38
64	64	for pain.— 39
65	65	(1) As used in this section, the term "nonopioid pain 40
66	66	drug" means a nonopioid drug approved by the United States Food 41
67	67	and Drug Administration for the treatment or management of pain. 42
68	68	(2) A managed care plan must provide coverage that does 43
69	69	not disadvantage or otherwise discourage a nonopioid pain drug 44
70	70	relative to any opioid or narc otic drug for the treatment or 45
71	71	management of pain. Prohibited practices or policies for such 46
72	72	coverage include, but are not limited to, the following: 47
73	73	(a) Designating a nonopioid pain drug as a nonpreferred 48
74	74	drug if any opioid or narcotic drug is designate d as a preferred 49
75	75	drug on the mandatory preferred drug list. 50
76	76
77	77	HB 1093 2025
78	78
79	79
80	80
81	81	CODING: Words stricken are deletions; words underlined are additions.
82	82	hb1093-00
83	83	Page 3 of 3
84	84	F L O R I D A H O U S E O F R E P R E S E N T A T I V E S
85	85
86	86
87	87
88	88	(b) Establishing utilization controls for a nonopioid pain 51
89	89	drug which are more restrictive or more extensive than the least 52
90	90	restrictive or extensive utilization controls applicable to any 53
91	91	opioid or narcotic drug used for treatment of the same 54
92	92	condition, including, but not limited to, imposing more 55
93	93	restrictive or more extensive prior authorization or step -56
94	94	therapy requirements for the nonopioid pain drug. 57
95	95	Section 3. This act shall take effect July 1, 2025. 58